other_material
confidence high
sentiment positive
materiality 0.65
Monopar reports positive long-term neurological data for ALXN1840 in Wilson disease
Monopar Therapeutics
- Pooled efficacy from 3 trials (n=255) showed sustained neurological improvement on UWDRS Part II & III over 6 years.
- Patients crossing from standard of care to ALXN1840 showed additional neurological improvement, reversing prior worsening.
- Psychiatric improvement sustained over multiple years per Brief Psychiatric Rating Scale (BPRS).
- Safety: <1% drug-related neurological serious adverse events across >645 patient-years on ALXN1840.
- Data presented at ANA Annual Meeting; builds on hepatic efficacy data from EASL 2025.
item 7.01item 9.01